CN107050434B - 包含重组hcg的药物制剂 - Google Patents
包含重组hcg的药物制剂 Download PDFInfo
- Publication number
- CN107050434B CN107050434B CN201610832288.8A CN201610832288A CN107050434B CN 107050434 B CN107050434 B CN 107050434B CN 201610832288 A CN201610832288 A CN 201610832288A CN 107050434 B CN107050434 B CN 107050434B
- Authority
- CN
- China
- Prior art keywords
- hcg
- sialylation
- rhcg
- sialyltransferase
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- 101100468640 Danio rerio rhcgl2 gene Proteins 0.000 claims abstract description 106
- 101150053759 rhcg gene Proteins 0.000 claims abstract description 106
- 210000005260 human cell Anatomy 0.000 claims abstract description 15
- 230000009450 sialylation Effects 0.000 claims description 77
- 210000004027 cell Anatomy 0.000 claims description 60
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 47
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 30
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 108090000141 Sialyltransferases Proteins 0.000 claims description 12
- 102000003838 Sialyltransferases Human genes 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 9
- 238000001890 transfection Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 abstract description 21
- 238000009472 formulation Methods 0.000 abstract description 4
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 138
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 138
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 132
- 238000002360 preparation method Methods 0.000 description 34
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 28
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 28
- 229940028334 follicle stimulating hormone Drugs 0.000 description 28
- 239000000047 product Substances 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- 102000001708 Protein Isoforms Human genes 0.000 description 19
- 108010029485 Protein Isoforms Proteins 0.000 description 19
- 125000005629 sialic acid group Chemical group 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 13
- 238000001155 isoelectric focusing Methods 0.000 description 12
- 210000002700 urine Anatomy 0.000 description 12
- 102000009151 Luteinizing Hormone Human genes 0.000 description 11
- 108010073521 Luteinizing Hormone Proteins 0.000 description 11
- 229940040129 luteinizing hormone Drugs 0.000 description 11
- 239000013604 expression vector Substances 0.000 description 10
- 150000004676 glycans Chemical group 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 239000002609 medium Substances 0.000 description 8
- 102100031974 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Human genes 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 6
- 102000004856 Lectins Human genes 0.000 description 6
- 108090001090 Lectins Proteins 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
- 229940015047 chorionic gonadotropin Drugs 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 239000002523 lectin Substances 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 208000000509 infertility Diseases 0.000 description 5
- 230000036512 infertility Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000002485 urinary effect Effects 0.000 description 5
- 102100029945 Beta-galactoside alpha-2,6-sialyltransferase 1 Human genes 0.000 description 4
- 241000699802 Cricetulus griseus Species 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 101000863864 Homo sapiens Beta-galactoside alpha-2,6-sialyltransferase 1 Proteins 0.000 description 4
- 101000703754 Homo sapiens CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 231100000535 infertility Toxicity 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 3
- 101710083574 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 102000006771 Gonadotropins Human genes 0.000 description 3
- 108010086677 Gonadotropins Proteins 0.000 description 3
- 102000023108 LH Receptors Human genes 0.000 description 3
- 108010011942 LH Receptors Proteins 0.000 description 3
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 3
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 3
- 102000005348 Neuraminidase Human genes 0.000 description 3
- 108010006232 Neuraminidase Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000005684 electric field Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 229960002442 glucosamine Drugs 0.000 description 3
- 239000002622 gonadotropin Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000006452 multicomponent reaction Methods 0.000 description 3
- 238000004305 normal phase HPLC Methods 0.000 description 3
- 230000016087 ovulation Effects 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HORYNJCIACQHGZ-BHVWUGLYSA-N 1-[(3R,4R,5S,6R)-3-amino-2,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]ethanone Chemical compound C(C)(=O)C1(O)[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO HORYNJCIACQHGZ-BHVWUGLYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical group N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 240000006028 Sambucus nigra Species 0.000 description 2
- 235000003142 Sambucus nigra Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- -1 and the like) Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001593 cAMP accumulation Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000008995 european elder Nutrition 0.000 description 2
- 230000033581 fucosylation Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940094892 gonadotropins Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 210000003370 receptor cell Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000687983 Cerobasis alpha Species 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241001521394 Maackia amurensis Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000005460 biophysical method Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000013373 clone screening Methods 0.000 description 1
- 235000021310 complex sugar Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 102000013361 fetuin Human genes 0.000 description 1
- 108060002885 fetuin Proteins 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000008217 follicular development Effects 0.000 description 1
- 108010081934 follitropin beta Proteins 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 229940057854 gonal f Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09252360.4 | 2009-10-05 | ||
| EP09252360 | 2009-10-05 | ||
| CN201080044470.8A CN102549011B (zh) | 2009-10-05 | 2010-10-04 | 包含重组hcg的药物制剂 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080044470.8A Division CN102549011B (zh) | 2009-10-05 | 2010-10-04 | 包含重组hcg的药物制剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107050434A CN107050434A (zh) | 2017-08-18 |
| CN107050434B true CN107050434B (zh) | 2021-07-27 |
Family
ID=41471027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610832288.8A Active CN107050434B (zh) | 2009-10-05 | 2010-10-04 | 包含重组hcg的药物制剂 |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US8975226B2 (enExample) |
| EP (2) | EP2486051B1 (enExample) |
| JP (6) | JP6176924B2 (enExample) |
| KR (7) | KR20230012104A (enExample) |
| CN (1) | CN107050434B (enExample) |
| AR (2) | AR079876A1 (enExample) |
| AU (1) | AU2010304922B2 (enExample) |
| BR (1) | BR112012007990A2 (enExample) |
| CA (1) | CA2776790A1 (enExample) |
| DK (1) | DK2486051T3 (enExample) |
| ES (2) | ES3036152T3 (enExample) |
| HR (1) | HRP20200941T1 (enExample) |
| HU (1) | HUE050793T2 (enExample) |
| IL (3) | IL218548A (enExample) |
| IN (1) | IN2012DN02073A (enExample) |
| JO (1) | JOP20200039A1 (enExample) |
| LT (1) | LT2486051T (enExample) |
| MX (1) | MX2012003951A (enExample) |
| PL (1) | PL2486051T3 (enExample) |
| PT (1) | PT2486051T (enExample) |
| RS (1) | RS60413B1 (enExample) |
| RU (2) | RU2588650C2 (enExample) |
| SI (1) | SI2486051T1 (enExample) |
| TW (2) | TWI604850B (enExample) |
| WO (1) | WO2011042688A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
| TWI604850B (zh) | 2009-10-05 | 2017-11-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| EP2691119B1 (en) | 2011-03-31 | 2018-08-01 | Ferring B.V. | Pharmaceutical preparation |
| EP2717904A1 (en) * | 2011-06-06 | 2014-04-16 | Ferring BV | Pharmaceutical preparation comprising recombinant fsh |
| JO3092B1 (ar) * | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
| WO2013093760A2 (en) * | 2011-12-19 | 2013-06-27 | Grifols, S.A. | Compositions, methods, and kits for preparing sialylated recombinant proteins |
| ES2738593T3 (es) | 2012-12-10 | 2020-01-23 | Seikagaku Kogyo Co Ltd | Factor C recombinante novedoso y método para producir el mismo, y método para medir endotoxina |
| EP3237608B1 (en) * | 2014-12-22 | 2019-10-09 | F. Hoffmann-La Roche AG | Cmp-dependent sialidase activity |
| EP3286209B1 (en) * | 2015-04-24 | 2020-11-25 | Ferring BV | Method of production of gonadotrophin |
| WO2016207353A1 (en) | 2015-06-26 | 2016-12-29 | Ferring B.V. | Methods of purification and/or viral inactivation |
| LT3787667T (lt) * | 2018-04-30 | 2025-05-12 | Ferring B.V. | Kompozicija, skirta kontroliuojamam kiaušidžių stimuliavimui |
| PH12022552029A1 (en) * | 2020-02-05 | 2023-11-20 | Novartis Ag | Cho cell expressing il-15 heterodimers |
| CN116199742B (zh) * | 2022-07-06 | 2025-01-24 | 华兰基因工程有限公司 | 一种重组人绒毛膜促性腺激素Fc融合蛋白制备方法 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004105788A1 (en) * | 2003-06-03 | 2004-12-09 | Ferring B.V. | UNITARY COMBINATION OF FSH AND hCG |
| CN1578838A (zh) * | 2001-10-29 | 2005-02-09 | 克鲁塞尔荷兰公司 | 生产具有预定的翻译后修饰的蛋白质的方法和手段 |
| CN1608078A (zh) * | 2001-10-22 | 2005-04-20 | 应用研究系统Ars股份公司 | 用于卵泡生成的促性腺激素 |
| WO2005076013A2 (en) * | 2004-02-04 | 2005-08-18 | Centre National De La Recherche Scientifique | Process for screening glycoform-specific antibodies |
| WO2005080585A1 (en) * | 2004-02-13 | 2005-09-01 | Glycotope Gmbh | Highly active glycoproteins-process conditions and an efficient method for their production |
| CN101177700A (zh) * | 2001-10-29 | 2008-05-14 | 克鲁塞尔荷兰公司 | 生产具有预定的翻译后修饰的蛋白质的方法和手段 |
| CN101516388A (zh) * | 2006-07-21 | 2009-08-26 | 诺和诺德公司 | 通过o-联糖基化序列的肽的糖基化 |
| WO2009127826A1 (en) * | 2008-04-16 | 2009-10-22 | Ferring International Center Sa | Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4840896A (en) * | 1983-11-02 | 1989-06-20 | Integrated Genetics, Inc. | Heteropolymeric protein |
| DK49987A (da) | 1987-01-30 | 1988-07-31 | Nordisk Gentofte | Fremgangsmaade til behandling af infertilitet og middel til anvendelse ved fremgangsmaaden |
| IT1206302B (it) | 1987-06-26 | 1989-04-14 | Serono Cesare Ist Ricerca | Ormone follicolo-stimolante urinario |
| EP0814841B1 (en) * | 1995-03-21 | 2001-12-05 | Applied Research Systems ARS Holding N.V. | Hcg liquid formulations |
| IL122732A0 (en) * | 1997-01-15 | 1998-08-16 | Akzo Nobel Nv | Liquid gonadotropin-containing formulation its preparation and a device containing same |
| US8530190B1 (en) | 1997-06-25 | 2013-09-10 | Merck Serono Sa | Disulfide crosslinked glycoprotein hormone analogs, and their preparation and use |
| US6500627B1 (en) | 1998-02-03 | 2002-12-31 | The Trustees Of Columbia University In The City Of New York | Methods for predicting pregnancy outcome in a subject by HCG assay |
| AR023869A1 (es) * | 1999-05-07 | 2002-09-04 | Serono Lab | Gonadotropinas |
| MXPA02007871A (es) * | 2000-02-22 | 2003-02-10 | Applied Research Systems | Proceso para la purificacion de gonadotropina corionica humana (hcg) y gonadotropina corionica humana recombinante purificada mediante este proceso. |
| AR036592A1 (es) | 2001-09-12 | 2004-09-22 | Applied Research Systems | Uso de gch en la hiperestimulacion ovarica controlada |
| WO2004099231A2 (en) * | 2003-04-09 | 2004-11-18 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| CN1374525A (zh) * | 2001-12-31 | 2002-10-16 | 陕西超英生物医学研究开发有限公司 | 一种抗体芯片、其制备技术及其检测方法 |
| EA200501548A1 (ru) * | 2003-04-01 | 2006-02-24 | Апплайд Резеч Системз Арс Холдинг Н.В. | Ингибиторы фосфодиэстераз при бесплодии |
| JP4518464B2 (ja) | 2003-06-30 | 2010-08-04 | ミヨシ油脂株式会社 | 紙類処理剤及び紙類 |
| US8017388B2 (en) * | 2003-08-18 | 2011-09-13 | Glycotope Gmbh | Tumour cell lines and uses thereof |
| CN101137396A (zh) * | 2005-03-11 | 2008-03-05 | 弗雷泽纽斯卡比德国有限公司 | 由无活性初始材料制备生物活性糖蛋白 |
| DE112006002122B4 (de) * | 2005-08-15 | 2016-09-22 | Continental Automotive Systems, Inc. ( n. d. Ges. d. Staates Delaware ) | Dieselabgas-Kohlenwasserstoff-Dosierventil für Fahrzeuge |
| RU2309411C2 (ru) * | 2005-11-24 | 2007-10-27 | Ростовский НИИ акушерства и педиатрии МЗ РФ | Способ отбора пациенток с синдромом "пустых" фолликулов для проведения программы эко и пэ донорскими ооцитами |
| KR100809945B1 (ko) * | 2006-02-01 | 2008-03-05 | 대한민국 | 인체장내정상세균총 특이반응 ｄｎａ칩 및 이를 이용한인체장내정상세균총의 변화에 의한 인체 위해성의 평가방법 |
| JP2010505874A (ja) * | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー／エス | ポリペプチドコンジュゲートの精製方法 |
| TWI604850B (zh) | 2009-10-05 | 2017-11-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| EP2691119B1 (en) * | 2011-03-31 | 2018-08-01 | Ferring B.V. | Pharmaceutical preparation |
| JO3092B1 (ar) * | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
-
2010
- 2010-09-27 TW TW104140348A patent/TWI604850B/zh active
- 2010-09-27 TW TW099132570A patent/TWI532495B/zh active
- 2010-10-04 EP EP10763000.6A patent/EP2486051B1/en active Active
- 2010-10-04 KR KR1020237001308A patent/KR20230012104A/ko active Pending
- 2010-10-04 SI SI201032015T patent/SI2486051T1/sl unknown
- 2010-10-04 PT PT107630006T patent/PT2486051T/pt unknown
- 2010-10-04 KR KR1020177034392A patent/KR20170133531A/ko not_active Withdrawn
- 2010-10-04 DK DK10763000.6T patent/DK2486051T3/da active
- 2010-10-04 US US13/500,274 patent/US8975226B2/en active Active
- 2010-10-04 CN CN201610832288.8A patent/CN107050434B/zh active Active
- 2010-10-04 HU HUE10763000A patent/HUE050793T2/hu unknown
- 2010-10-04 KR KR1020197016021A patent/KR102213154B1/ko active Active
- 2010-10-04 ES ES19190372T patent/ES3036152T3/es active Active
- 2010-10-04 MX MX2012003951A patent/MX2012003951A/es active IP Right Grant
- 2010-10-04 RS RS20200698A patent/RS60413B1/sr unknown
- 2010-10-04 AU AU2010304922A patent/AU2010304922B2/en active Active
- 2010-10-04 BR BR112012007990A patent/BR112012007990A2/pt not_active Application Discontinuation
- 2010-10-04 HR HRP20200941TT patent/HRP20200941T1/hr unknown
- 2010-10-04 KR KR1020217037028A patent/KR102489143B1/ko active Active
- 2010-10-04 ES ES10763000T patent/ES2798258T3/es active Active
- 2010-10-04 EP EP19190372.3A patent/EP3611185B1/en active Active
- 2010-10-04 WO PCT/GB2010/001854 patent/WO2011042688A1/en not_active Ceased
- 2010-10-04 IN IN2073DEN2012 patent/IN2012DN02073A/en unknown
- 2010-10-04 LT LTEP10763000.6T patent/LT2486051T/lt unknown
- 2010-10-04 KR KR1020217003233A patent/KR20210014767A/ko not_active Ceased
- 2010-10-04 KR KR1020197007226A patent/KR101987982B1/ko active Active
- 2010-10-04 JP JP2012532657A patent/JP6176924B2/ja active Active
- 2010-10-04 RU RU2012112907/10A patent/RU2588650C2/ru active
- 2010-10-04 RU RU2016118236A patent/RU2724528C2/ru active
- 2010-10-04 CA CA2776790A patent/CA2776790A1/en active Pending
- 2010-10-04 KR KR1020127008827A patent/KR101804479B1/ko active Active
- 2010-10-04 PL PL10763000T patent/PL2486051T3/pl unknown
- 2010-10-05 AR ARP100103608A patent/AR079876A1/es not_active Application Discontinuation
-
2012
- 2012-03-08 IL IL218548A patent/IL218548A/en active IP Right Grant
-
2014
- 2014-05-21 US US14/283,904 patent/US9676835B2/en active Active
-
2015
- 2015-11-09 JP JP2015219480A patent/JP6310440B2/ja active Active
-
2017
- 2017-02-23 IL IL250733A patent/IL250733B/en active IP Right Grant
- 2017-05-03 US US15/586,010 patent/US10526390B2/en active Active
- 2017-10-24 JP JP2017205012A patent/JP6580104B2/ja active Active
-
2019
- 2019-06-20 IL IL267556A patent/IL267556A/en unknown
- 2019-08-27 JP JP2019154226A patent/JP7292153B2/ja active Active
- 2019-12-10 US US16/709,810 patent/US11292824B2/en active Active
-
2020
- 2020-02-17 JO JOP/2020/0039A patent/JOP20200039A1/ar unknown
-
2021
- 2021-07-12 JP JP2021114833A patent/JP7196244B2/ja active Active
-
2022
- 2022-03-30 US US17/709,296 patent/US12234272B2/en active Active
- 2022-05-27 AR ARP220101408A patent/AR125991A2/es not_active Application Discontinuation
-
2023
- 2023-02-22 JP JP2023025781A patent/JP2023075144A/ja active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1608078A (zh) * | 2001-10-22 | 2005-04-20 | 应用研究系统Ars股份公司 | 用于卵泡生成的促性腺激素 |
| CN1578838A (zh) * | 2001-10-29 | 2005-02-09 | 克鲁塞尔荷兰公司 | 生产具有预定的翻译后修饰的蛋白质的方法和手段 |
| CN101177700A (zh) * | 2001-10-29 | 2008-05-14 | 克鲁塞尔荷兰公司 | 生产具有预定的翻译后修饰的蛋白质的方法和手段 |
| WO2004105788A1 (en) * | 2003-06-03 | 2004-12-09 | Ferring B.V. | UNITARY COMBINATION OF FSH AND hCG |
| CN1826135A (zh) * | 2003-06-03 | 2006-08-30 | 凡林有限公司 | FSH和hCG的单一组合 |
| WO2005076013A2 (en) * | 2004-02-04 | 2005-08-18 | Centre National De La Recherche Scientifique | Process for screening glycoform-specific antibodies |
| WO2005080585A1 (en) * | 2004-02-13 | 2005-09-01 | Glycotope Gmbh | Highly active glycoproteins-process conditions and an efficient method for their production |
| CN1926242A (zh) * | 2004-02-13 | 2007-03-07 | 格莱克托普有限公司 | 高活性糖蛋白加工条件及其有效生产方法 |
| CN101516388A (zh) * | 2006-07-21 | 2009-08-26 | 诺和诺德公司 | 通过o-联糖基化序列的肽的糖基化 |
| WO2009127826A1 (en) * | 2008-04-16 | 2009-10-22 | Ferring International Center Sa | Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation |
Non-Patent Citations (3)
| Title |
|---|
| Hard K.等.The carbohydrate chains of the β subunit of human chorionic gonadotropin produced by the choriocarcinoma cell line BeWo.《European Journal of Biochemistry》.1992,第205卷(第2期),摘要，讨论部分，表1，第786页左边栏第2段. * |
| Structure and Location of the 0-Glycosidic Carbohydrate Units of Human Chorionic Gonadotropin;Michael J. Kessler等;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;19790825;第254卷(第16期);7909-7914 * |
| The carbohydrate chains of the β subunit of human chorionic gonadotropin produced by the choriocarcinoma cell line BeWo;Hard K.等;《European Journal of Biochemistry》;19921231;第205卷(第2期);摘要，讨论部分，表1，第786页左边栏第2段 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107050434B (zh) | 包含重组hcg的药物制剂 | |
| ES2989729T3 (es) | FSH recombinante que incluye sialilación en alfa 2,3 y alfa 2,6 | |
| CN103619358B (zh) | 药物制剂 | |
| CN102549011B (zh) | 包含重组hcg的药物制剂 | |
| HK40020346A (en) | Pharmaceutical preparation | |
| HK1174338B (en) | Pharmaceutical preparation comprising recombinant hcg | |
| HK1174338A (en) | Pharmaceutical preparation comprising recombinant hcg | |
| Class et al. | Patent application title: Pharmaceutical Preparation Comprising Recombinant HcG Inventors: Ian Cottingham (St. Prex, CH) Daniel Plaksin (St. Prex, CH) Richard Boyd White (San Diego, CA, US) Assignees: Ferring BV |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |